The FDA recently approved a non-opioid analgesic known as suzetrigine. It has a novel mechanism of action involving selective inhibition of the voltage-gated sodium channel 1.8. This inhibition only reduces peripheral pain signaling pathway

Lawmakers in the United Kingdom are considering stricter controls for the drug ketamine. While it is licensed in the UK as an anaesthetic and for pain relief for short-term use, there has been a concerning increase in its misuse.

Based on epidemiological data and the European Medicines Agency’s decision to communicate findings to healthcare professionals, SAHPRA has recommended